文献速递特殊人群用药治疗药物监测与药物基因组学

肿瘤放射诊疗一体化的临床药理学

Clinical Pharmacology of Radiotheranostics in Oncology.
PubMed 文献 · Clin Pharmacol Ther · 2022-05-10

文章还讨论了成纤维细胞活化蛋白、CXCR4、胃泌素释放肽受体等新靶点及剂量优化、多受体靶向、放射增敏、药物基因组学等提高疗效的策略。强调新型放射配体的设计与剂量优化需多学科协作并纳入临床药理学。

要点

  • 放射诊疗一体化利用同一分子靶点的诊断与治疗配体实现患者筛选和靶向治疗。
  • 生长抑素类似物和PSMA配体分别在神经内分泌肿瘤和前列腺癌显示临床疗效。

核心结论

  • 放射诊疗一体化可实现对肿瘤患者的准确筛选、靶向治疗和疗效预测。
  • 多种放射配体已在甲状腺癌、骨转移、嗜铬细胞瘤/副神经节瘤、神经母细胞瘤、神经内分泌肿瘤和前列腺癌中应用或显示疗效。
  • 新型放射配体的设计及剂量方案优化需多学科协作并纳入临床药理学。

研究设计与样本

  • 本文为综述,未报告系统检索范围、纳入文献数量或样本量。

主要发现

  • 放射性标记生长抑素类似物和前列腺特异性膜抗原配体分别在神经内分泌肿瘤和前列腺癌治疗中显示临床疗效。
  • 多种候选化合物正靶向成纤维细胞活化蛋白、C-X-C趋化因子受体4和胃泌素释放肽受体等新型诊疗靶点。
  • 剂量学指导的剂量优化、多受体靶向、靶受体上调、放射增敏、药物基因组学和放射基因组学等策略正在评估以提高放射配体治疗疗效。

临床怎么用

  • 临床选择放射配体治疗时应基于同一分子靶点的诊断性显像进行患者筛选。
  • 放射配体治疗的剂量和方案优化应结合剂量学及多学科协作,并纳入临床药理学考量。

局限性

  • 本文为综述,未报告系统检索策略、纳入研究数量及偏倚评估。
  • 文中未提供具体疗效数值、剂量方案或安全性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The combined use of diagnostic and therapeutic radioligands with the same molecular target, also known as theranostics, enables accurate patient selection, targeted therapy, and prediction of treatment response. Radioiodine, bone-seeking radioligands and norepinephrine analogs have been used for many years for diagnostic imaging and radioligand therapy of thyroid carcinoma, bone metastases, pheochromocytoma, paraganglioma, and neuroblastoma, respectively. In recent years, radiolabeled somatostatin analogs and prostate-specific membrane antigen ligands have shown clinical efficacy in the treatment of neuroendocrine tumors and prostate cancer, respectively. Several candidate compounds are targeting novel theranostic targets such as fibroblast activation protein, C-X-C chemokine receptor 4, and gastrin-releasing peptide receptor. In addition, several strategies to improve efficacy of radioligand therapy are being evaluated, including dosimetry-based dose optimization, multireceptor targeting, upregulation of target receptors, radiosensitization, pharmacogenomics, and radiation genomics. Design and evaluation of novel radioligands and optimization of dose and dose schedules, within the complex context of individualized multimodal cancer treatment, requires a multidisciplinary approach that includes clinical pharmacology. Significant increases in the use of these radiopharmaceuticals in routine oncological practice can be expected, which will have major impact on patient care as well as (radio)pharmacy utilization.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Te Beek ET, Burggraaf J, Teunissen JJM, et al. Clinical Pharmacology of Radiotheranostics in Oncology. Clin Pharmacol Ther. 2022. PMID: 35373336. doi:10.1002/cpt.2598

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。